Invested in MiRTeL Co., LTD.

NTT DOCOMO Ventures, Inc. (headquartered in Minato-ku, Tokyo, Japan; President & CEO: Minoru Etoh) announced today its investment, through the investment fund it operates, in MiRTeL Co., LTD. (headquartered in Hiroshima-shi, Hiroshima, Japan; Chairman & CEO: Hidetoshi Tahara, hereinafter referred to as "MiRTeL") that provides a genetic test named the "MiRTeL Test" by using its proprietary technology.

1 Overview of the investment

NTT DOCOMO Ventures, Inc., through the investment fund it operates, has subscribed for unsecured convertible bonds of MiRTeL.

2 Background

MiRTeL is engaged in disease prevention by using its proprietary technology "MiRTeL Test," which screens people at a genetic level for potential diseases. NTT DOCOMO, INC. (headquartered in Chiyoda-ku, Tokyo, Japan; President & CEO: Kaoru Kato, hereinafter referred to as "DOCOMO") and MiRTeL will start a joint health innovation study to promote the nation's healthy longevity. By combining DOCOMO's ICT knowledge and MiRTeL's expertise on disease screening and prevention, we expect to create a new healthy longevity business.